Literature DB >> 21997355

Bevacizumab and type 1 idiopathic macular telangiectasia.

C L Koay, F L M Chew, S Visvaraja.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21997355      PMCID： PMC3234482          DOI： 10.1038/eye.2011.252

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia.

Authors:  K Takayama; S Ooto; H Tamura; K Yamashiro; A Otani; A Tsujikawa; N Yoshimura
Journal:  Eye (Lond)       Date:  2010-04-30       Impact factor: 3.775

2.  Idiopathic juxtafoveolar retinal telangiectasia: a review and case report.

Authors: 
Journal:  Clin Eye Vis Care       Date:  2000-03-01

3.  Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.

Authors:  Rodrigo Jorge; Rogério A Costa; Daniela Calucci; Ingrid U Scott
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-29       Impact factor: 3.117

4.  Bevacizumab in the treatment of idiopathic macular telangiectasia.

Authors:  Maria-Andreea Gamulescu; Andreas Walter; Helmut Sachs; Horst Helbig
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

5.  Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.

Authors:  Jaclyn L Kovach; Philip J Rosenfeld
Journal:  Retina       Date:  2009-01       Impact factor: 4.256
  5 in total
  6 in total

1.  Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.

Authors:  Buğra Karasu; Betul Onal Gunay
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-25       Impact factor: 3.117

2.  Macular oedema related to idiopathic macular telangiectasia type 1 treated with dexamethasone intravitreal implant (ozurdex).

Authors:  Mohamed Loutfi; Thomas Papathomas; Ahmed Kamal
Journal:  Case Rep Ophthalmol Med       Date:  2014-06-17

3.  Macular oedema in idiopathic macular telangiectasia type 1 responsive to aflibercept but not bevacizumab.

Authors:  O'Sam Shibeeb; Anagha Vaze; Mark Gillies; Timothy Gray
Journal:  Case Rep Ophthalmol Med       Date:  2014-10-01

4.  EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.

Authors:  Laura Kowalczuk; Alexandre Matet; Ali Dirani; Alejandra Daruich; Aude Ambresin; Irmela Mantel; Richard F Spaide; Natacha Turck; Francine Behar-Cohen
Journal:  Retina       Date:  2017-12       Impact factor: 4.256

5.  CLINICAL FEATURES OF TREATED AND UNTREATED TYPE 1 IDIOPATHIC MACULAR TELANGIECTASIA WITHOUT THE OCCURRENCE OF SECONDARY CHOROIDAL NEOVASCULARIZATION FOLLOWED FOR 2 YEARS IN JAPANESE PATIENTS.

Authors:  Rie Osaka; Chieko Shiragami; Aoi Ono; Mamoru Kobayashi; Yukari Takasago; Ayana Yamashita; Akitaka Tsujikawa
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

6.  Multimodal Imaging Findings and Treatment with Dexamethasone Implant in Three Cases of Idiopathic Macular Telangiectasia Type 1.

Authors:  Paola Cirafici; Maria Musolino; Michela Saccheggiani; Carlo Enrico Traverso; Massimo Nicolò
Journal:  Case Rep Ophthalmol       Date:  2021-04-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.